Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer

NCT01522443 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

119

Enrollment

INDUSTRY

Sponsor class

Stopped Stopped after the outcome of cabozantinib Phase 3 CRPC study XL184-307.

Conditions

Prostate Cancer
Castration Resistant Prostate Cancer
Pain
Prostatic Neoplasms

Interventions

DRUG: cabozantinib
DRUG: mitoxantrone
DRUG: prednisone

Sponsor

Exelixis